A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Niraparib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 30 Dec 2024 to 30 Dec 2026.
- 04 Feb 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2026.
- 04 Feb 2025 Status changed from recruiting to active, no longer recruiting.